Suggestions
Henry Peck
Vice President, Strategy at LSI | Medtech and Healthtech Engineer, Marketer, Investor, and Community Builder
Henry Peck is the Vice President of Growth & Strategy at LSI (Life Science Intelligence), a company that provides market intelligence and partnering events for the medtech industry.12 He joined LSI in November 2022, transitioning from being a fan of the company to a key executive role.24
Peck's background is in biomedical engineering and medtech. He holds a Bachelor of Science in Mechanical Engineering from Carnegie Mellon University, where he also pursued additional studies in English.1 His career has spanned various roles in the medical technology sector, including:
- Director of Marketing & Strategy at Altoida, Inc., where he worked on predicting neurological diseases using technology.3
- Clinical Engineer in Robotics & Digital Solutions at Johnson & Johnson, where he was involved in developing the Ottava robot-assisted laparoscopic surgery platform.1
- Product Manager at Galen Robotics, working on minimally invasive microsurgery solutions.1
Peck's journey into medtech was inspired by his personal experience with a rare optical condition, which led to his passion for improving health and medicine.1 He brings interdisciplinary experience in product development, marketing, commercial strategy, and community building to his role at LSI.4
At LSI, Peck is involved in expanding the business and launching innovative solutions for the medtech community. His role leverages his understanding of the convergence of healthcare, technology, and the digital world.4
Highlights
Who has strong opinions on Quality of Founder vs Quality of Market in venture?
LSI has long been a trusted partner for medtech market data and insights. It's now my mission to help the "so what?" of these insights reach more people, and tap into our global community to put data in context of what's happening in the innovation and investment ecosystem.
Last week, I began writing an article with my team that's drawing on insights sourced from leading #LSIAlumni investors, including contributions from Soyoung Park, Dr. Luc Marengere, Armen Vidian, Dr. Gal Noyman - Veksler, David Kereiakes, Kevin Chu, Owen Willis, Adam Rosenwach and more.
Here's the prompt I provided:
The saying in traditional venture goes "market determines how big a company can get, founder determines how big a company will get." Does that hold in Medtech and Healthtech? Would our top investors rather invest in a company building in a huge market being attacked by a good founder, or a modest market attacked by a spectacular founder?
Just in the replies from these investors, the learnings are tremendous....and the alignment and differentiation between them is fascinating. Can't wait to finish writing in the coming weeks.
Look out for the final article which will be released on our website's Insights Hub, and let me know your thought in the comments (have room to incorporate a few more great perspectives in to the mix for this one).
PS - In case you haven't seen yet, our team at LSI has been putting out Insights and articles on everything from the Global Neuromodulation Market to the $129B+ in unnecessary Blood Transfusion-related costs in the US Alone.
Check out what we've been thinking about on our site, and get in touch if you have an idea or want to contribute to the Insights Hub - https://lnkd.in/ep9vVC9i
Bain Capital Ventures just launched an AI VC chatbot (link in the comments) and I've been stuck in the liminal space between deep reflection and hysterical laughter since I opened it 🙃
The AI VC lets you pitch your company, respond to AI-generated follow-up questions a “VC” would ask, and negotiate deal terms. I’ve only run a couple full conversations with it, but here are my thoughts.
On the potential for this and similar tools...
→ Could the initial screening portion of a high volume of inbound dealflow be done with generative AI tools? There’s plenty of type-and-fill applications, forms, etc. used by investors to collect inbound interest, is this a logical extension to get deeper, more personalized information on a company in screening?
→ Could this be trained to be hyper-personalized pitch prep? If you ask ChatGPT to write a script for a comedy special, it can write jokes. But, if you ask it to write in the style of Sarah Silverman or Dave Chapelle, it can mimic their unique comedic style almost to a T. Could this tool be trained to mimic the behavior and style of iconic VCs, and eventually the key leaders at a fund you may pitch? If so, simulating your pitch could actually be useful.
→ If everyone is pouring their ideas and “company” information into this AI, the owner of that AI may have access to some unique data. Notice in my conversation with the AI (image attached) after telling me my idea was stupid (which it is) it asked if I had done any market research. If I had done proprietary research to validate this idea and fed it into this dialogue, it may realize “oh wow this is a good idea” or at the very least now it has access to market research it didn't have before. There’s something to be done with that at scale.
Now. on the other hand…
→ It offered me a $1M equity investment at a $20M valuation for my company; a hypothetical nonsense idea of paint-resistant-paint, so college students can play indoor paintball without destroying their houses. It made that offer after asking me 1 question. Pretty far from the norm I'd say.
→ It has a “leaderboard” tracking who can “close a deal” with the AI for the biggest raise at the best deal terms. There’s some wild numbers in there, go check it out. Excited to learn more about "dmo.ooo" the company at the top of the leaderboard, having just closed a hypothetical $30T for 0%! Is the company worth an infinite amount? No idea.
And of course, special shoutout to @VapesForDogs...a company that I must assume is fake, but, if not, now may soon have $10M in fresh capital to bring strawberry-flavored nicotine air to a poodle near you.
Give it a try using the link in the comments. Happy negotiating!
